Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine for hypermetabolic amyotrophic lateral sclerosis
ACTRN12620000945921Phase 2Completed
- Sponsor
- The University of Queensland
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of trimetazidine in amyotrophic lateral sclerosis (ALS), sponsored by The University of Queensland. Primary endpoints: Safety and tolerability of trimetazidine at Week 16 and Change from baseline in oxidative stress markers at Week 16. Started Jun 2021; status: completed.
02
Drugs
trimetazidine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ACTRN12620000945921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000945921.